Renegotiating budgets for long-term extensions: why an annual maintenance fee beats a higher visit rate

When a study moves into a long extension, the work that keeps it alive does not shrink in proportion to the visit schedule, and a budget built only on per-visit payment quietly stops covering the cost of staying open. The fix is not an ever-higher visit rate. It is to unbundle the fixed costs — regulatory upkeep, pharmacy oversight, record retention, and trained staff availability — into a transparent annual maintenance fee, priced at the extension amendment and tied to the number of participants who remain. That structure is fairer for the site, and more predictable for the sponsor.

The extension math that breaks site budgets

The main treatment phase of a trial is busy by design. Visits are frequent, and per-visit revenue arrives often enough to carry the people and systems behind the study. An extension phase reverses that arithmetic: a study can run for three to six more years with only two to four visits per participant per year and only a handful of participants remaining at a site.

Nothing about that pace makes the study inexpensive to hold. It makes revenue intermittent while obligations stay continuous. If the budget pays only when a participant walks through the door, the site absorbs months of fixed cost between small, widely spaced payments. Over a multi-year extension, that gap is a structural deficit, and it grows as the remaining participant count falls, because the fixed work does not fall at the same rate.

Arguing over the visit rate alone therefore fails both sides. Raising it high enough to cover a year of fixed cost makes a single visit look disproportionately expensive, and still leaves payment mistimed. The visit rate was designed to pay for visit work — not for the standing cost of keeping a study compliant and ready between visits.

What per-visit payment does not pay for

A per-visit fee properly covers the work of the visit itself: the assessments performed that day, staff time with the participant, the procedures, and the data generated by that encounter. An extension carries a second category of work that exists whether or not anyone is scheduled this month.

Regulatory upkeep continues. The site must maintain current approvals, process amendments, and keep documentation ready for review by the institutional review board (IRB) — the independent committee charged with protecting the rights and welfare of research participants. Delegation logs, training records, and essential documents must stay current for the principal investigator (PI) — the clinician responsible for the conduct of the study at the site — and for every team member who might touch the study.

Pharmacy and investigational product oversight continues when a product remains on site; accountability, storage monitoring, and temperature documentation do not pause between visits. Record retention continues for the full period required by the protocol and applicable regulation. Staff availability is a real cost as well: a coordinator who knows the protocol and a backup who can cover an unscheduled safety visit cannot be reassembled at no cost on the morning a participant finally returns.

None of this is invented work. Each item protects participants, data integrity, and the sponsor's inspection readiness. At Amavita Research Services, our Miami cardiovascular trial site, we work from a panel of more than 18,000 active cardiology patients and a record of zero findings on Food and Drug Administration (FDA) Form 483 — the form agency investigators use to record inspectional observations. That record is maintained by funding the standing work every month, whether the calendar is full or quiet.

Unbundle the budget at the amendment

The moment to fix the structure is the extension amendment. That is when leverage exists, for a practical reason: the sponsor needs sites to agree to keep participants followed, keep data flowing, and keep the study open for years beyond the original plan. Once the amendment is signed on the old terms, the conversation becomes a request for relief. Before it is signed, it is a negotiation about what the extended work actually costs.

Unbundling means separating the budget into two honest parts. The first remains per-visit payment for visit work, at a rate that can be defended as visit work. The second is an annual maintenance fee for the fixed cost of keeping the study alive at that site for that year. Present both together, with the inventory behind the second part made visible. Sponsors resist vague requests for more money far more than they resist a defined list of obligations with a defined annual price.

How to structure an annual maintenance fee

A workable fee has four elements, and each should be written into the clinical trial agreement (CTA) — the contract between the sponsor and the site that sets the terms, responsibilities, and payment for the study — rather than left to an email exchange.

First, define what the fee covers, by category: regulatory maintenance, pharmacy oversight, record storage and retention, systems and quality oversight, and minimum trained staffing coverage. Second, set the fee on an annual cycle, paid at the start of each extension year or in equal quarterly installments, so payment timing matches the continuous timing of the work. Third, tie the fee to a remaining-participant band. A larger remaining cohort carries more scheduling, query, and follow-up load, so the fee can step down in defined bands as participants complete or withdraw, with a floor level for the smallest band — some fixed costs remain even for a single participant. Fourth, include a re-opener: if the sponsor changes the visit cadence, adds procedures, extends the phase again, or materially changes reporting requirements, the fee is revisited on defined terms rather than absorbed silently.

Add a fifth protection: an annual escalator. A fee fixed for a five-year extension loses value every year while wages, storage, and systems costs rise. A modest escalator, expressed as a stated annual percentage or tied to a named published index, keeps the agreement realistic.

Build the figures from your own site's actual costs. Treat any example structure — bands, percentages, or installment schedules — as illustrative structure only, never as an industry benchmark. Your payroll, rent, storage contracts, and overhead are the evidence a sponsor can test.

How to price it without padding it

Start with an inventory, not a number. List every fixed obligation the extension imposes for one year, then attach the time and direct cost your site actually spends on each one: hours for regulatory maintenance, hours for pharmacy checks and accountability, the annual cost of compliant storage, the share of quality and systems cost the study carries, and the minimum coordinator and investigator coverage needed to respond safely and promptly.

Divide shared costs by a consistent allocation method you can explain.

Finally, test the result against the alternative the sponsor faces if sites decline the extension: transferring participants, losing long-term data, or reopening site selection for a small remaining cohort. A defined annual fee is not an added luxury. It is the price of continuity for data the sponsor has already invested years in collecting. As CEO of Amavita Research Services, and as CEO of bioaccess — a first-in-human contract research organization (CRO), meaning a company sponsors engage to help design and run early-stage trials — I see this from both sides of the table. Continuity has value, and continuity has cost. A good budget names both.

Why this is fairer for the sponsor, too

Sponsors should prefer this structure for their own reasons. An annual fee converts an unpredictable future dispute into a known line item finance teams can forecast for the full extension period. It removes the incentive to recover fixed costs by inflating visit rates, and it reduces the risk of a mid-extension closure driven not by performance but by quiet economics — the most expensive outcome of all for long-term data. In return, it buys defined obligations: maintained approvals, trained coverage, accountable product handling, and retrievable records.

Ask for the fee at the amendment, present the inventory, tie it to participant bands, add the escalator and the re-opener, and put all of it in the CTA. Do that, and a long extension stops being a slow loss a site endures for its participants. It becomes a defined service, fairly priced, that both sides can plan around.